Home/ Stocks/ MGNX

MacroGenics, Inc.

MGNX XNAS

$3.00 +0.15 (+5.10%) ▲ 15-min delayed

Open

$2.96

High

$3.10

Low

$2.90

Volume

814.2K

Market Cap

$190.68M

About MacroGenics, Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 293 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$149.50M	$-74,620,000	$-1.18
FY 2025	$149.50M	$-74,620,000	$-1.18
Q3 2025	$72.84M	$16.82M	$0.27
Q2 2025	$22.24M	$-36,251,000	$-0.57

Related Market News

No specific coverage for MGNX yet. Check out our latest market news or earnings calendar.

Get MGNX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on MacroGenics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.